STOCK TITAN

APDN Form 4: Director now holds 22,512 shares after RSU grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Applied DNA Sciences (APDN): A director reported acquiring 22,511 shares of common stock at $0 on 10/17/2025 via a restricted stock unit grant. Following the transaction, the director beneficially owned 22,512 shares, held directly.

The award vests 100% 90 days from the grant date, indicating a short vesting schedule before settlement into shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ceccoli Joseph D.

(Last) (First) (Middle)
50 HEALTH SCIENCES DRIVE

(Street)
STONY BROOK NY 11790

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
APPLIED DNA SCIENCES INC [ BNBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 10/17/2025 A 22,511 A $0 22,512 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 100% of the restricted stock units vest upon 90 days from the date of grant
/s/ Beth Jantzen, Attorney-in-Fact 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did APDN disclose in this Form 4?

A director acquired 22,511 common shares at $0 on 10/17/2025 from an RSU grant.

How many APDN shares does the reporting person own after the transaction?

The filing shows 22,512 shares beneficially owned directly after the transaction.

What are the vesting terms for the APDN RSU grant?

The filing states 100% of the restricted stock units vest 90 days from the date of grant.

What was the price per share reported in the transaction?

The transaction price was reported as $0, consistent with an RSU grant.

What was the transaction date for the APDN Form 4?

The transaction date reported is 10/17/2025.

Was the ownership direct or indirect after the transaction?

The filing lists Direct (D) ownership following the reported transaction.
Applied Dna Scie

NASDAQ:APDN

APDN Rankings

APDN Latest News

APDN Latest SEC Filings

APDN Stock Data

7.26M
1.28M
1.11%
6.92%
8.4%
Diagnostics & Research
Services-testing Laboratories
Link
United States
STONY BROOK